TuHURA Biosciences, Inc. (NASDAQ:HURA) announced on November 4, 2026, that it will present three poster presentations on its Delta Opioid Receptor (DOR) research at the 68th American Society of Hematology Annual Meeting and Exposition, scheduled for December 12-15, 2026, in New Orleans, Louisiana.

Key Highlights

  • Three posters scheduled: Abstract numbers 4725, 4721, and 4744 will each be presented at the ASH 68th Annual Meeting in New Orleans.
  • Presentation date and time: All three posters are scheduled for Monday, December 14, 2026, from 6:00 p.m. to 8:00 p.m. ET, in MCCNO Hall F.
  • Primary presenter: Dr. Krit Ritthipichai, Director of Immunology, is listed as presenter on all three abstracts; Dr. Taekyoung Kwak, Lead Scientist, Immunology, is co-presenter on abstract 4721.
  • Research focus: The posters address DOR inhibition's effects on MDSCs, T regs, and M2 macrophages, including gene expression changes in Cxcl10, Saa3, and Acod1, as well as PENK gene expression and mENK protein levels.
  • Patent relevance noted: According to the filing, the data provide "information critical to multiple patent submissions," as stated by Dr. James Bianco, President and CEO.
  • ADC development referenced: The company described the DOR technology as a basis for developing "first new class of non-tumor targeting, immune modulating ADCs," according to the press release.

TuHURA's DOR Research at ASH 2026: Poster Details and Scientific Scope

According to the filing, TuHURA Biosciences will present findings from its ongoing Delta Opioid Receptor (DOR) research program at the 68th ASH Annual Meeting. The company described the DOR as "a novel target central to the regulation of multiple genes involved in immune suppression, chemotaxis and proliferation of immune suppressing cells in cancer and autoimmune disease including MDSCs, T regs, and M2 macrophages."

Abstract 4725, to be presented by Dr. Ritthipichai, covers DOR inhibition on MDSCs and its effects on Cxcl10, Saa3, and Acod1 gene expression, characterizing DOR as "a single target to modulate MDSC proliferation, migration and immune suppression," per the filing. Abstracts 4721 and 4744 share the same title, focusing on how DOR inhibition drives proenkephalin (PENK) gene expression and met-enkephalin (mENK) protein in tumor-derived MDSCs and bone marrow-derived macrophage subtype 2 cells, with stated implications for cancer and autoimmune disease. Abstract 4721 lists both Dr. Kwak and Dr. Ritthipichai as presenters, while abstract 4744 lists Dr. Ritthipichai alone.

In a statement attributed to Dr. Bianco in the filing, TuHURA indicated that the DOR data "underscore the breadth of the potential therapeutic applications for DOR technology in the development of a first new class of non-tumor targeting, immune modulating ADCs." The filing notes that TuHURA is also running a Phase 3 trial of IFx-2.0 in Merkel Cell Carcinoma and a Phase 1b trial of TBS-2025 in patients with mutNPM1 r/r AML. The press release contains forward-looking statements and directs readers to the company's cautionary language and regulatory filings for associated risks.

What Was Disclosed

TuHURA Biosciences announced three poster presentations on DOR research for the 68th ASH Annual Meeting on December 14, 2026, in New Orleans. The posters cover DOR inhibition effects on MDSCs, T regs, and M2 macrophages, with relevance to cancer immunotherapy resistance and autoimmune disease.